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Background: The purpose of the present study is to introduce an adapted protocol of in vivo exposure for fear
avoidant back pain patients and its implementation in the German health care system without multidisciplinary
teams. Case studies demonstrated promising effects but three preceding randomized controlled trials (RCTs) could
not support the former results. More empirical support is necessary to further substantiate the effectiveness of
in vivo exposure.
Methods: A total of 108 chronic low back pain patients are randomly assigned to one out of three conditions
(A: exposure_long (15 sessions), B: exposure_short (10 sessions) or C: control condition cognitive behavioral therapy
(15 sessions)). The inclusion criteria are: back pain ≥3 months and a sufficient level of fear-avoidance. An effect
evaluation, a process evaluation and an economic evaluation are conducted. Primary outcomes are pain-related
disability and pain intensity. Secondary outcomes are: emotional distress, fear avoidance, catastrophizing and costs.
Data are collected at baseline, upon completion of the intervention, after 10 sessions, and at six months following
completion of treatment. Besides the comparison of exposure in vivo and cognitive behavioral therapy (CBT), we
additionally compare a short and a long version of exposure to analyze dose response effects.
Discussion: This is, to our knowledge, the first RCT comparing in vivo exposure to psychological treatment as usual
in terms of cognitive behavioral therapy. Results will help to find out whether a tailored treatment for fear avoidant
back pain patients is more effective than a general pain management treatment.
Trial registration: The trial has been registered to ClinicalTrial.gov. The trial registration number is NCT01484418.
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Chronic low back pain (CLBP) is one of the most com-
mon health problems in Western societies. In Europe,
one out of every five people experiences significant back
pain that infers with quality of life [1]. In addition to its
broad prevalence, CLBP is one of the major causes of
medical expenses, work absenteeism and disability [2].
Since cognitive behavioral models of CLBP have become
more widely accepted, a large variety of behavioral* Correspondence: glombiew@staff.uni-marburg.de
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reproduction in any medium, provided the orinterventions have become available for the treatment of
CLBP [3]. Psychological interventions have been found to
be effective, with cognitive behavioral treatments showing
moderate to large effect sizes for reducing self-reported
pain, pain-related interference, depression and disability
[4]. However, it is unknown which interventions work best
for particular subgroups of patients [3,5,6] and more
research is needed to define subgroups [5]. Vlaeyen and
colleagues developed a treatment focusing on fear-
avoidant back pain patients [7]. This treatment, known as
graded in vivo exposure, is based on the fear-avoidance
model of chronic pain, which postulates that fear and
avoidance of movement contributes to the maintenance ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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forces disability [8]. As in the treatment of anxiety
disorders, the patient is gradually exposed to a feared
stimulus, which in the case of CLBP is movement believed
to lead to pain or potential injuries to the back. Approxi-
mately 10 years ago, the first single case designs showed
that in vivo exposure reduced pain disability, pain
catastrophizing, and pain-related fears with large effect
sizes [7,9-11]. In addition to the case studies, three ran-
domized controlled trials (RCTs) have compared graded
exposure to a waiting list, graded activity programs [12,13]
or treatment as usual, for example, usual medical care
[14]. These studies found that in vivo exposure was supe-
rior to control conditions at reducing pain-related fears
and catastrophizing. Only one study found effects (at the
trend level) on pain-related disability [14]. In summary,
the efficacy of exposure treatment in the RCTs was infer-
ior relative to the preceding case studies.
Therefore, as emphasized by the authors of previously
published systematic reviews, additional RCTs, including
larger sample sizes, cost-effectiveness-analyses, media-
tional analyses and treatment fidelity assessments, are
required [15-17].
Problem definition
Several questions concerning exposure in vivo treatment
(EXP) for chronic back pain remain unanswered:
First, there is a lack of empirical evidence regarding
whether interventions tailored for particular subgroups,
such as in vivo exposure for fear-avoidant pain patients,
are more effective than traditional cognitive behavioral
treatments for the management of chronic pain problems
(CBT-P). Although a variety of definitions of CBT exist,
we favor the description provided by Turk, which incor-
porates behavioral (principles of learning), emotional and
cognitive factors. Thus, we attempt to teach our patients
“to recognize the connections linking cognitions, affective,
behavioral, and physiologic responses together with their
joint consequences” [18]. Thus far, in vivo exposure has
not been compared to cognitive behavioral treatment as it
is usually delivered in clinical practice.
Second, it is unknown how many sessions of EXP are
needed to achieve sufficient results and that patients get the
needed benefit. In a single case paradigm, Vlaeyen et al.
found significant reductions in disability and pain-related
fears after only three exposure sessions [7]. On the other
hand, recent reviews indicate that there is evidence that
prolonged psychological treatment in chronic pain patients
is beneficial [19,20]. Hansen and colleagues showed that
between 13 and 18 sessions of therapy in general are
required for 50% of patients to improve [21]. Besides the re-
search on the dose–response relationship in psychotherapy
in general it is also very important to evaluate and develop
the adequate treatment of more specialized treatmentapproaches. Thus, the analysis of the dose–response
relationship in exposure treatment for chronic pain is
needed to establish an effective and economical length of
treatment.
Third, CLBP is often described as a socio-economic
problem because it is a major cause of medical expenses,
work absenteeism and disability [2]. However, economic as-
pects of CLBP treatments (for example, cost-effectiveness)
have generally received little attention and thus should be
incorporated into RCTs [5,22].
Objectives
The present investigation, which began recruitment in
August 2011 and is currently ongoing, utilizes a three-
arm randomized controlled trial method to assess the
efficacy of graded in vivo exposure (EXP) for CLBP rela-
tive to cognitive behavioral therapy (CBT-P). To our
knowledge, this is the first study to implement in vivo
exposure for CLBP patients in an outpatient setting in
Germany, and is also the first study to compare graded
in vivo exposure to CBT. Accordingly, we will assess the
feasibility of this new treatment approach. Dose-effects
will be analyzed by comparing a short and a long version
of EXP. In addition, cost-effectiveness will be evaluated.
Besides, the main questions meditational analyses and
examination of effects of generalization are planned.
Research questions
1) Is EXP more effective (at post-treatment and at six-
month follow-up) at reducing pain-related disability
and pain intensity (primary outcomes) as well as
other symptoms compared to CBT-P in patients
with fear-avoidance beliefs?
2) Are there any differences in treatment effects
between the short (10 sessions) and the long (15
sessions) versions of exposure at post-treatment and
at six-month follow-up?




A three-arm randomized controlled clinical trial will
be performed in a university-based outpatient clinic in
Marburg (Psychotherapieambulanz der Universität
Marburg, PAM), Germany.
Patients are assigned to one of three conditions (A:
exposure_long; B: exposure_short or C: control condi-
tion, specifically cognitive behavioral therapy for the
management of chronic pain).
The study includes assessments at baseline, mid-
treatment, post-treatment and six-month follow-up, as
well as process measures.
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Participants
Our target sample is 108 patients with CLBP. Potential
study patients will be recruited via advertisements in local
newspapers, doctors´ offices and from the waiting list of
our outpatient clinic. Potential participants are screened
through an initial phone interview with a research assis-
tant examining the basic inclusion criteria. Those who
fulfill all of the basic criteria are invited to a second
screening in our outpatient clinic where the criteria of
fear-avoidance and disability are assessed.
Inclusion and exclusion criteria
Patients with CLBP are included if they meet all of the
following criteria:
1. Basic criteria:
1.1Chronic low back pain for at least three months.
1.2Age: 18 to 66.
2. Additional criteria:
2.1TSK (Tampa Scale of Kinesiophobia) [23] ≥35 or
Phoda-Profile (Photo Series of Daily Activities)
[24]: harm ratings of 13 activities >50, including 8
>80 (range 0 to 100, with 0 = “not harmful at all”
and 100 = “extremely harmful for my back”).
2.2Sufficient level of disability, as defined by QBPDS
≥15 (Quebec Back Pain Disability Scale) [25].
Exclusion criteria include: back surgeries during the last
six months or planned surgeries, Red Flags [26], inability
to read or write in German, pregnancy, alcohol addiction,
psychotic disorders and current psychological treatment.
Patients are excluded if they are unable to attend sessions
regularly for physical or psychological reasons.
Physical and psychological comorbidities, such as de-
pression, are not exclusionary so long as patients are able
to attend sessions and complete homework. Recruitment
started in August 2011 and will continue until the target
sample of 108 patients with CLBP is achieved (expected to
occur near the end of 2013). We anticipate that this
timeframe will be adequate to achieve recruitment goals.
Sample size calculation
To identify the target number of participants we used
the G-Power Analysis software program (University of
Düsseldorf, Germany www.psycho.uni-duesseldorf.de/
abteilungen/aap/gpower3.) [27]. Based on the effects of
previous RCTs, we expected a small effect group x time
(repeated measures) of 0.2 for the comparison of three
groups (assuming an alpha level = 0.05, two-tailed, β = 0.95,
correlation between measurements = 0.5). Results of the
power analysis indicated a required sample size of 36participants per group, for a total of 108. The data will
be analyzed with the intent-to-treat (ITT) approach
using the last value carried forward and including all pa-
tients who intended to participate, regardless of whether
they dropped out or not.
Patient allocation and randomization
Patients are randomized to one of three conditions fol-
lowing a predetermined and computer-generated ran-
domization schedule, pre-stratified by degree of pain
catastrophizing (PCS) [28] and disability (PDI) [29]. The
median scores of the pain catastrophizing and disability
data from a previous study are used as cutoffs. Within
each stratum, a randomized block design with a block size
of nine is used to ensure equal distribution of important
patient characteristics. The randomization procedure is
performed by a blinded research assistant who prepares
sequentially numbered, sealed, opaque envelops. As is
common in psychological treatments, it was not feasible
to blind patients or therapists to treatment condition.
Intervention
We translated and adapted the protocol of Johan Vlaeyen
and Jeroen de Jong [7] for implementing EXP in a German
outpatient setting. The intervention is delivered by two
PhD students who are clinical psychologists and who re-
ceived two different sessions of training from J. Vlaeyen
and J. de Jong. In addition, each session is supervised
afterwards by experienced psychologists. The control con-
dition is a cognitive behavioral treatment for pain patients
containing basic elements for the management of chronic
pain that are standard in our outpatient clinic. The treat-
ment includes graded activity, relaxation (progressive
muscle relaxation) and cognitive interventions such as
cognitive restructuring (Table 1). Both interventions are
offered in a structured, individual setting with weekly
appointments of 50 minutes.
Treatment sessions are video-recorded and a random
selection of videos is evaluated for treatment fidelity.
Two blinded raters independently assess protocol adhe-
rence, treatment contamination and whether the treat-
ments can be differentiated from each other using the
method of assessing treatment delivery in clinical trials
(MATD) [30]. In advance, treatment elements of both
treatments were identified and listed in a randomized
order for the ratings.
Common features
Both treatments aim to restore functioning and to
decrease pain-related disability. The first two sessions of
all treatment conditions are identical. At the intake, par-
ticipants receive printed material, including background
information and worksheets. The first appointment
serves as an anamnesis interview which is followed by
Table 1 Overview treatment sessions
Session EXP_long EXP_short CBT_P


























5 Exposure 1 Exposure 1 Graded Activity I
6 Exposure 2 Exposure 2 Graded Activity II
7 Exposure 3 Exposure 3 Health Behavior
8 Exposure 4 Exposure 4 Progressive Relaxation I
9 Exposure 5 Exposure 5 Progressive Relaxation II
10 Exposure 6 Completion Cognitive Intervention I: Attention
Shifting
11 Exposure 7 Cognitive Intervention II:
Identification of automatic
thoughts and core beliefs about
pain
12 Exposure 8 Cognitive Intervention III:
Restructuring of dysfunctional
thoughts and beliefs
13 Exposure 9 Individual Session I
14 Exposure 10 Individual Session II
15 Completion Completion
CBT-P, Cognitive behavioral treatment for chronic pain problems; EXP,
Exposure treatment.
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general information about pain, factors related to the
maintenance of pain, and physical and physiological
changes associated with chronic pain are discussed.
Finally, all patients are encouraged to develop feasible
treatment goals with respect to activities in which they
would like to re-engage.EXP - unique features
Graded in vivo exposure (Table 1) aims to reduce pain-
related disability via overcoming fear of pain/movements.
The program offers two versions of exposure: a long form
including 15 sessions (10 exposures) and a short form
including 10 meetings (5 exposure sessions). After the first
two sessions, the patient is encouraged to develop an indi-
vidualized fear-avoidance model including pain, pain
cognitions and avoidance. This circular model serves as a
basis for transferring and explaining the therapeutic ra-
tionale. During session four, a fear hierarchy is establishedusing the Photo Series of Daily Activities [31]. The patient
makes harm ratings of 100 pictures showing daily activities.
If the patient has understood the therapeutic rationale and
is willing to do exposure he will be gradually confront
feared stimuli, which are movements related to pain or po-
tential injuries of the back. Patients are encouraged to en-
gage in these feared activities as much as possible until
anxiety levels have decreased. Behavioral experiments are
integrated to challenge catastrophic beliefs about the feared
consequences of pain or specific movements. This inter-
vention is intended to produce cognitive and behavioral
changes and offers the patient the opportunity to regain
trust in his or her body. The process of overcoming fear
and learning that feared consequences are unlikely to occur
is believed to be the main mechanism of treatment.
CBT-P unique features
The primary goal of the CBT approach is the same as that
of the exposure treatment, that is, to increase functional
capacity. However, the method used to achieve this goal is
different. CBT-P encourages patients to develop an adaptive
style of coping by maintaining a problem-solving orienta-
tion. Patients are provided with different strategies to cope
with pain. Initially, patients learn to increase activity by di-
viding the activities they want to perform in smaller steps
to avoid phases of excessive demands followed by long
terms of recovery. After this first phase, patients learn to
practice progressive relaxation. During the third module,
maladaptive pain-related cognitions are identified and
discussed. Patients are taught to recognize the links bet-
ween thoughts, feelings and behavior and to challenge
negative appraisals as one strategy for interrupting pain-
maintaining circuits. The last two sessions are individua-
lized based on topics relevant to the patient (for example,
work-related problems). These topics are discussed with a
focus on problem-solving.
An additional table file gives an overview of the treat-
ment sessions in more detail (see Additional file 1,
Table 1).
Outcomes
For outcomes related to pain, we followed the recommen-
dations from the Initiative on Methods, Measurements,
and Pain Assessment in Clinical trials (IMMPACT, [32]).Primary outcome measures
Pain-related disability is measured using the Pain
Disability Index (PDI) [29,33] and the Quebec Back Pain
Disability Scale (QBPDS) [25].
Pain intensity is assessed four times a day using a two-
week pain diary comprising an 11-point numeric rating
scale (NRS) (0 = no pain, 10 = pain at its worst) and an
11-point scale from the German Pain Questionnaire
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intensity during the past four weeks [34].
Secondary outcomes
Fear of movement/pain anxiety is measured using the
Tampa Scale of Kinesiophobia (TSK) [23,35] and The
Pain Anxiety Symptom Scale (PASS) [36,37]
Pain catastrophizing is assessed using the Pain
Catastrophizing Scale (PCS) [28,38].
Emotional distress is measured using the Hospital
Anxiety and Depression Scale (HADS) [39,40].
Quality of Life is measured using the EuroQol Ques-
tionnaire (EQ-5D) [41,42].
Pain vigilance is measured using the Pain Vigilance
and Attention Questionnaire (PVAQ) [43,44].
Physical activity is assessed using the International
Physical Activity Questionnaire (IPAQ) [45].
Global perceived effect of treatment is rated on a 7-point
scale (1 = completely recovered, 7 = worse than ever) to
assess subjective perceptions of recovery.
All instruments have been widely used and demon-
strated reliability and validity in the chronic pain
population.
Tertiary outcomes
The tertiary outcomes include: the Pain Solutions
Questionnaire (PASOL) [46], the Psychological Inflexibi-
lity in Pain Scale (PIPS) [47], scales assessing coping with
pain (Fragebogen zur Erfassung der Schmerzverarbeitung,
FESV) [48] and the Pain Self Efficacy Questionnaire
(FESS) [49].
Additional variables
Several additional variables are assessed in order to
examine potential mechanisms of treatment and to
assess feasibility and treatment fidelity.
Satisfaction with treatment as a measure of feasibility is
evaluated with 10 items on an 11-point scale (0 = strongly
disagree, 10 = absolutely agree). In addition, the therapists
assessed feasibility in a qualitative manner including a
standardized dropout evaluation and assessment of
adverse effects.
All therapy sessions are documented within a table,
including notes and information about the participants
based on evaluations of the therapists or supervision. The
therapist also notes when he or she thinks that the
assigned treatment approach is not fully adequate for this
patient. Furthermore, a standardized dropout evaluation
was developed. If a patient breaks off treatment, an
independent research assistant asks the participant stan-
dardized questions about the reasons for refusing the
treatment and possible adverse effects of treatment.
Sessions will be evaluated for treatment fidelity by a
research assistant blind to treatment conditions. Thefidelity evaluation is based on the approach of Leeuw
and colleagues who developed a method of assessing
treatment delivery in clinical trials (MATD) [30].
Treatment expectancy and rationale credibility is mea-
sured with the credibility and expectancy questionnaire
(CEQ) [50].
The therapeutic alliance is measured on an 11-point scale
including 13 items (0 = strongly disagree, 10 = absolutely
agree).
Process evaluation
Participants complete a short survey online each week
to measure mediating variables relevant to the process
of change. The battery includes the TSK, PDI, IPAQ,
QBPDS, a numeric rating scale assessing pain severity,
and an 11-item scale assessing coping with pain, self-
efficacy and avoidance rated on an 11-point scale.
Economic evaluation
Costs and expenses are evaluated using an adapted version
of the short form of the Trimbos/iMTA questionnaire for
costs associated with psychiatric illness over the past
month (TIC-P) [51]. The total costs include direct health-
care and non-health care costs (that is, travel costs, out-of
pocket expenses, self-paid medical care), as well as indi-
rect health care costs due to loss of productivity. Direct
health-care costs include costs of health-care consump-
tion in general (that is, general practitioner, physical
therapists, hospital visits and so on.). The number of con-
sultations is multiplied by the cost of each visit to calculate
total costs.
Data collection
Data are collected at baseline (T0), after 10 sessions (T1,
completion of EXP short), upon completion of the inter-
vention (T2), and six months following completion of
treatment (T3). Thus, participants in the short version
of EXP complete only three assessments. Questionnaires
are completed at home via the internet. This procedure
reduces missing data and helps to keep study therapists
blind to outcome data. Supplemental evaluations are
carried out weekly, including process variables. If pa-
tients do not have internet access the assessment are
provided on a computer in our outpatient clinic. Video
recordings are carried out during each session to gather
objective data for later analysis of treatment fidelity.
Data analysis
The latest version of The Statistical Package for Social
Science (IBM SPSS Statistics) version 19is used for data
analyses. Intention-to-treat analyses (ITT) used to ac-
count for deviations from random allocation and missing
data. A repeated measures design will be used with pri-
mary and secondary measures as dependent variables,
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surement as the within-subjects factor.
Possible confounding variables (for example, duration of
complaints) will be considered and included as covariates
according to the results of correlation analyses. Effect sizes
(Cohen´s d) will be calculated to determine the magnitude
of the mean differences between groups on the outcome
variables. According to Cohen´s guidelines, an effect size
of .2 indicates a small effect, .5 a medium effect and .8 a
large effect [52]. We consider a 30% reduction on the
NRS to indicate clinically important change on the core
outcome measure of pain intensity [53]. The economic
evaluation consisted of a cost-utility analysis and a cost-
effectiveness analysis. For both analyses, the incremental
cost-effectiveness ratio (ICER) was calculated as (C1-C0)/
(E1-E0) where C is the cost and E is the effect and the ex-
perimental and comparator conditions are indexed with
the 1, 0 subscripts.
The incremental cost-utility ratio will focus on the net
costs per quality adjusted life years (QALY) gained. The
cost-effectiveness ratio focuses on the net costs per
reliable and clinically improved case of disability/pain.
Probit analysis will be used for dose–response effects.
This approach based on probability theory and includes
determining the observed rates and resulting probability
of a response for a particular treatment.
Ethical considerations
Before participating, each patient receives and signs an in-
formed consent form, which describes the details of the
intervention and assessments. Participants are informed321 applied for
71 met selection crite
27 allocated to EXP_long 23 allocated to
Completed
n = 13 
166 fulfilled the 





Figure 1 Flow of participants (07/06/2013).that they may cease participation at any time without con-
sequences. In addition, participants are offered standard
psychotherapy at our outpatient clinic if needed. The Eth-
ics committee of The German Association of Psychology
(DGPS, WR 052010_1) approved this trial.
Discussion
General
Despite the demonstrated efficacy of cognitive behavioral
interventions for the treatment of CLBP [4], research on
the efficacy of EXP is lacking [16]. To our knowledge, this
is the first study to implement EXP in an outpatient
setting in Germany. Furthermore, it is the first rando-
mized clinical trial to evaluate EXP compared to cognitive
behavioral treatment as usual for chronic pain. This com-
parison allows us to investigate whether fear-avoidant
back pain patients benefit more from a treatment that ad-
dresses their specific pain-related fears than from a
general psychological pain management program.
EXP is a relatively new approach for treating CLBP.
During the process of developing and testing new inter-
ventions, it is important to investigate feasibility, cost-
effectiveness and the underlying mechanism of treatment
change. A recent review called for additional RCTs investi-
gating approaches to CLBP [15], and with one exception
[54], existing published RCTs have not investigated mech-
anisms of change [17]. To understand the process of
change during EXP, the current RCT adds weekly mea-
sures of potential key mediators, such as self-efficacy, pain
coping and pain beliefs. A novel feature of the current
study is the inclusion of a short form of exposure therapy participation
ria and were randomized







Dropouts n = 155
- 32 did not met 
fear-avoidance criteria
- 30 refrained from screening
- 14 unwilling to participate
- 4 not contactable
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sessions. The analysis of the dose–response relationship in
exposure treatment is crucial to determining an effective
and economical treatment length. Finally, as EXP repre-
sents a completely new approach in the German health
care system, information about cost-effectiveness is very
important. In general, information on the economic as-
pects of CLBP treatments is lacking [5,22]. Accordingly,
we integrated cost-effectiveness analysis with an adapted
version of the TIC-P [51].
Potential strengths of the study protocol
Participants will be recruited over a period of two years,
which allows the inclusion of a larger sample (108 par-
ticipants) relative to a prior RCT (N = 59) [12].
Before administering the intervention, the therapists par-
ticipated in two workshops taught by Johan Vlaeyen and
Jeroen de Jong, the developers of in vivo exposure for
CLBP. This training ensures that therapists have basic
knowledge and competence in implementing the treatment.
Weekly supervision is provided, and therapeutic difficulties
are discussed as a team. In addition, our research team is in
regular contact with the groups in Maastricht and Leuven.
Regular meetings allow discussion of specific difficulties
with treatment implementation. It has been observed that
the quality of treatment is frequently neglected in studies
evaluating therapeutic interventions [4,16]. Accordingly, to
improve the quality of the treatment protocol, adherence
will be assessed through video-recordings of sessions and
will be controlled in analyses. The Method of Assessing
Treatment Delivery (MATD) proposed by Leeuw and col-
leagues [30] will be used to assess treatment fidelity.Potential limitations of the study protocol
The treatment in the present study is designed for patients
with CLBP with sufficient levels of fear and avoidance
(TSK ≥35, Phoda-profile), and thus it is unclear whether
results are likely to generalize beyond this specific pain
population. Nevertheless, we attempted to keep the eligi-
bility criteria very liberal (that is, no exclusion for
comorbidities or medication use, moderate level of TSK)
to offer broad access to the intervention. Secondly, the
present study relies largely on self-report measures.Conclusions
It is important to determine whether a specialized treat-
ment is needed for fear-avoidant back pain patients, a high-
risk group characterized by substantial impairment, or
whether standard CBT programs are adequate? This RCT
provides an opportunity to address this question by investi-
gating whether in vivo exposure is more effective than psy-
chological treatment as usual for the treatment of CLBP.
Furthermore, the results of this study will be used toestablish the feasibility and cost-effectiveness of in vivo
exposure in an outpatient psychological setting.
Trial status
Recruitment of patients started on August 2011 and will
proceed until the end of 2013. Data on the effect, process
and economic evaluation are expected to be available in
2014. A total of 71 participants had been enrolled and
randomized for this trial by May 2013 (Figure 1).
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